PM
ZYN is doing the heavy lifting
UBS took a pair of scissors to Philip Morris International’s price target, cutting it to $168 from $181.50 while sticking with a Neutral rating. The reason? Less optimism around U.S. ZYN volumes, which the firm now sees at 800 million cans for fiscal 2026 versus a consensus of 895 million.
That’s not exactly the kind of revision that makes growth investors do cartwheels. ZYN has been one of the nicotine business’s hotter storylines, so when an analyst dials back volume expectations, it’s basically a reminder that even a buzzy product still has to, you know, actually sell.
The good news: pricing still helps
UBS didn’t torch the whole thesis. It also lifted its net price assumption and still expects Philip Morris to deliver double-digit U.S. dollar EPS growth of 11.6% this year. So this is less “the story is broken” and more “the runway is a little bumpier than people wanted.”
Not the only note hitting the tape
Stifel also trimmed its target on Philip Morris to $195 from $200, though it kept a Buy rating. That one came with a different excuse: foreign exchange headwinds. Same stock, different worry. Classic Wall Street buffet.
Meanwhile, there’s the Ferrari side quest
Philip Morris also said it has entered into a partnership with Ferrari Hypersail, extending a relationship that started in Formula 1 and now stretches into ocean racing. Because apparently the next best thing after selling nicotine products is branding yourself onto very fast things on land and sea.
Big picture: PM still has growth levers, but analysts are getting a little less dreamy about how quickly ZYN can scale. For investors, that means the stock story is still alive — just with fewer victory laps and more spreadsheet squinting.